NCT03385655 2025-08-21
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT02788773 2025-05-15
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03204812 2024-10-15
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00378482 2024-08-22
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Phase 2 Completed